Dr Sarah Nickolls

Sarah is a group leader in the Screening Profiling and Mechanistic Biology department at GlaxoSmithKline. After completing her PhD in molecular pharmacology she undertook post-doctoral studies at Neurocrine Biosciences, in San Diego. Upon returning to the UK she joined Pfizer, where she became a research project leader. She has considerable across a number of different target and therapy areas including pain and neuroscience. Sarah joined GSK in 2016.